Lack of Economic Benefit With Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients

Jason A. Crompton, Pharm.D., Troy Somerville, Pharm.D., Lonnie Smith, Pharm.D., Jacke Corbett, FNP-C, Edward Nelson, M.D., John Holman, M.D., Fuad S. Shihab, M.D.


Pharmacotherapy. 2003;23(4) 

In This Article


The results of our study indicate that BAS is safe but not cost-effective in LRD renal transplant recipients. Given high survival rates of this population, augmentation of a triple-drug regimen with induction immunosuppression may not provide additional benefit. The IL-2R antagonists may serve only to increase patient and institution costs without further benefit on graft survival.

Presented in part at the annual meeting of the American College of Clinical Pharmacy, Tampa, Florida, October 22, 2001.